Verrica Pharmaceuticals Inc. (VRCA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$13.10M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$9.71M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $1.63M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $1.51M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$13.10M | (m) | (m) | (m) | (m) | -$9.28M* | (m) | $6.03M | $10.35M | (m) |
| 2026-03-31 | Reported | (m) | -$9.71M | (m) | (m) | (m) | (m) | -$9.16M | (m) | $3.86M | $9.99M | (m) |
| 2025-09-30 | Reported | (m) | $1.63M | (m) | (m) | (m) | $0.00* | $9.69M* | (m) | $2.21M | $9.40M | (m) |
| 2025-06-30 | Reported | (m) | $1.51M | (m) | $12.70M | (m) | (m) | -$10.04M* | (m) | $1.85M | $8.85M | (m) |
| 2025-03-31 | Reported | (m) | -$8.13M | (m) | $3.44M | (m) | (m) | -$12.68M | (m) | $2.28M | $8.85M | (m) |
| 2024-09-30 | Reported | (m) | -$20.70M | (m) | -$1.78M | (m) | $16.00K* | -$8.56M* | (m) | $2.40M | $16.08M | (m) |
| 2024-06-30 | Reported | (m) | -$15.21M | (m) | $5.18M | (m) | $11.00K* | -$16.36M* | (m) | $3.32M | $16.52M | (m) |
| 2024-03-31 | Reported | (m) | -$18.60M | (m) | $3.83M | (m) | $0.00 | -$19.95M | (m) | $4.95M | $16.34M | (m) |
| 2023-09-30 | Reported | (m) | -$23.92M | (m) | $2.92M | (m) | $65.00K* | -$14.81M* | (m) | $6.51M | $20.05M | (m) |
| 2023-06-30 | Reported | (m) | -$11.62M | (m) | $182.00K | (m) | $59.00K* | -$4.67M* | (m) | $5.72M | $5.94M | (m) |
| 2023-03-31 | Reported | (m) | -$7.09M | (m) | $37.00K | (m) | $11.00K | -$4.59M | (m) | $2.74M | $4.32M | (m) |
| 2022-09-30 | Reported | (m) | $1.45M | (m) | $8.32M | (m) | $77.00K* | $1.82M* | (m) | $2.78M | $3.92M | (m) |
| 2022-06-30 | Reported | (m) | -$9.12M | (m) | $214.00K | (m) | $154.00K* | -$7.18M* | (m) | $3.94M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$7.41M | (m) | $431.00K | (m) | $5.00K | -$8.34M | (m) | $2.44M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$11.77M | (m) | $0.00 | (m) | $39.00K* | -$10.60M* | (m) | $3.76M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$10.73M | (m) | $0.00 | (m) | $296.00K* | $2.50M* | (m) | $3.45M | (m) | (m) |
| 2021-03-31 | Reported | (m) | $60.00K | (m) | $12.00M | (m) | $311.00K | -$10.79M | (m) | $5.36M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$9.64M | (m) | (m) | (m) | $111.00K* | -$7.61M* | (m) | $4.99M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$8.63M | (m) | (m) | (m) | $116.00K* | -$8.59M* | (m) | $3.52M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$9.88M | (m) | (m) | (m) | $699.00K | -$7.91M | (m) | $4.89M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$7.99M | (m) | (m) | (m) | (m) | (m) | (m) | $3.97M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$6.54M | (m) | (m) | (m) | (m) | -$7.23M* | (m) | $3.05M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$7.52M | (m) | (m) | (m) | (m) | -$5.05M* | (m) | $3.93M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$8.03M | (m) | (m) | (m) | (m) | -$6.92M | (m) | $4.49M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$8.19M | (m) | (m) | (m) | (m) | (m) | (m) | $4.92M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$6.33M | (m) | (m) | (m) | $13.00K* | -$5.14M* | (m) | $3.47M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$5.47M | (m) | (m) | (m) | $94.00K* | -$3.68M* | (m) | $3.52M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$1.89M | (m) | (m) | (m) | $17.00K | -$2.15M | (m) | $927.00K | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$1.43M | (m) | (m) | (m) | (m) | (m) | (m) | $1.12M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$1.36M | (m) | (m) | (m) | (m) | -$1.07M* | (m) | $1.12M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$1.09M | (m) | (m) | (m) | (m) | (m) | (m) | $977.00K | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$570.00K | (m) | (m) | (m) | (m) | (m) | (m) | $515.00K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$12.19M | (m) | (m) | (m) | $0.00 | -$17.63M | (m) | $8.86M | $35.22M | $0.00 |
| 2024-12-31 | Reported | (m) | -$65.92M | (m) | $7.57M | (m) | $27.00K | -$60.93M | (m) | $11.84M | $58.82M | $0.00 |
| 2023-12-31 | Reported | (m) | -$65.76M | (m) | $5.12M | (m) | $362.00K | -$38.58M | (m) | $20.30M | $47.30M | $0.00 |
| 2022-12-31 | Reported | (m) | -$21.30M | (m) | $9.03M | (m) | $302.00K | -$18.65M | (m) | $12.20M | $17.41M | $0.00 |
| 2021-12-31 | Reported | (m) | -$30.91M | (m) | $12.00M | (m) | $883.00K | -$27.58M | (m) | $15.93M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$40.18M | (m) | (m) | (m) | $1.47M | -$30.21M | (m) | $15.67M | (m) | (m) |
| 2020-09-30 | Rolling | (m) | -$36.14M* | (m) | (m) | (m) | (m) | (m) | (m) | $17.37M* | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$33.04M* | (m) | (m) | (m) | (m) | (m) | (m) | $15.43M* | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$31.93M* | (m) | (m) | (m) | (m) | (m) | (m) | $15.84M* | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$30.08M | (m) | (m) | (m) | $682.00K | -$27.41M | (m) | $15.44M | (m) | (m) |
| 2019-12-31 | Rolling | (m) | -$30.08M* | (m) | (m) | (m) | (m) | (m) | (m) | $15.44M* | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$30.28M* | (m) | (m) | (m) | (m) | (m) | (m) | $16.38M* | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$30.07M* | (m) | (m) | (m) | (m) | (m) | (m) | $16.80M* | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$28.02M* | (m) | (m) | (m) | (m) | (m) | (m) | $16.39M* | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$21.88M | (m) | (m) | (m) | $774.00K | -$17.87M | (m) | $12.83M | (m) | (m) |
| 2018-12-31 | Rolling | (m) | -$21.88M* | (m) | (m) | (m) | (m) | (m) | (m) | $12.83M* | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$15.12M* | (m) | (m) | (m) | (m) | (m) | (m) | $9.03M* | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$10.15M* | (m) | (m) | (m) | (m) | (m) | (m) | $6.68M* | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$5.78M* | (m) | (m) | (m) | (m) | (m) | (m) | $4.14M* | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$4.46M | (m) | (m) | (m) | (m) | -$4.58M | (m) | $3.73M | (m) | (m) |
| 2017-12-31 | Rolling | (m) | -$4.46M* | (m) | (m) | (m) | (m) | (m) | (m) | $3.73M* | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |